Wire · opportunities
Sequencing FGFR2 Inhibitors in Previously Treated Cholangiocarcinoma
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 30 September 2026 · Fusion42 review
Following FDA approval of lirafugratinib for cholangiocarcinoma, oncologists face a strategic choice among three FGFR2 inhibitors—pemigatinib, futibatinib, and lirafugratinib—balancing efficacy, resistance mutation activity, and tolerability without head-to-head trial data.
This Wire brief sits within Fusion42's coverage of Biotech, and 10 sources have reported it between 16 Sep 2026 and 5 Oct 2026.
◆ ◆ The Wire takeaway
Cholangiocarcinoma treatment founders should prioritise developing clear head-to-head clinical data or companion diagnostic tools to help oncologists choose between FGFR2 inhibitors, as this decision now shapes patient care and market uptake. Resistance mutation targeting and patient tolerability profiles have become key leverage points to win clinical preference and market share.
◆ Coverage
10 sources · first reported 16 Sep 2026 · latest 5 Oct 2026
◆ Topics